Table 4.

Relative mortality rate between calcium acetate and calcium carbonate users

Hazard Ratioa95% CIP
Univariate1.070.88 to 1.300.48
Adjusted for demographic variables (age, gender, race, ethnicity)1.070.89 to 1.300.47
Additionally adjusted for marital status, living situation, educational level, comorbidities,b and baseline dialysis modality1.020.84 to 1.240.84
Additionally adjusted for BP and laboratory measurementsb1.010.83 to 1.230.94
Additionally adjusted for use of other medicationsb1.020.84 to 1.240.84
Propensity score–matched cohort (n = 2278)1.020.83 to 1.250.86
  • a Calcium carbonate users constituted the reference group.

  • b Comorbidities include coronary heart disease, congestive heart failure, chronic obstructive lung disease, cerebrovascular disease, history of cardiac arrest, hypertension, diabetes, HIV positivity, malignancy, and peripheral artery vascular disease. Laboratory measurements include serum phosphate, calcium, parathyroid hormone, albumin, total cholesterol, and triglyceride concentrations. Other medications include statins, angiotensin-conversion enzyme inhibitors, angiotensin-receptor blockers, and beta blockers.